/
HBIO
$6.13+$0.08 (+1.41%)prev close
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$27.2M
5M shares
52-week range
$3.76 – $9.40
42% from low
Sector
LABORATORY ANALYTICAL INSTRUMENTS
Exchange
NASDAQ
CS
Borrow rate
0.50%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-76.28
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $120.8M | $116.2M | $102.1M | $118.9M | $113.3M | $112.3M | $94.1M | $86.5M |
| Cost of revenue | $57.6M | $51.9M | $44.1M | $51.3M | $52.5M | $46.2M | $39.4M | $40.7M |
| Gross profit | $63.2M | $64.3M | $58.0M | $67.7M | $60.8M | $66.1M | $54.8M | $45.9M |
| Gross margin | 52.3% | 55.4% | 56.8% | 56.9% | 53.7% | 58.9% | 58.2% | 53.0% |
| R&D | $11.0M | $10.7M | $8.7M | $10.8M | $12.3M | $11.8M | $10.4M | $8.8M |
| Operating income | $984.0K | $377.0K | $221.0K | $2.1M | −$6.9M | $1.9M | −$6.2M | −$629.0K |
| EBITDA | $5.4M | $7.6M | $5.2M | $9.0M | $944.0K | $8.0M | −$1.5M | −$46.5M |
| Net income | −$3.5M | −$4.7M | −$7.8M | −$288.0K | −$9.5M | −$3.4M | −$12.4M | −$56.7M |
| Net margin | -2.9% | -4.0% | -7.6% | -0.2% | -8.4% | -3.0% | -13.2% | -65.5% |
| EPS (diluted) | -0.95 | -1.20 | -2.00 | -0.07 | -2.30 | -0.81 | -2.80 | -12.80 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $89M | $-0.70 | $-0.71–$-0.69 | 1 |
| 2027 | $94M | $0.44 | $0.30–$0.58 | 2 |
| 2028 | $87M | $0.00 | $0.00–$0.00 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Harvard Bioscience Inc
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, products, and services that enable advances in life science applications, including research, drug and therapy discovery, bioproduction, and preclinical testing. The company organizes its product line into two product families: Cellular and Molecular Technologies (CMT) and Preclinical. The CMT product family supports molecular, cellular, organ, and organoid research, as well as bioproduction and in vitro testing, while the Preclinical product family provides products for preclinical research and testing, including data collection and analysis for safety and regulatory compliance. Its geographical segments include the Americas, Europe, Middle East and Africa, and Asia.
www.harvardbioscience.com- Employees
- 339
- IPO / List date
- Dec 7, 2000
- HQ
- HOLLISTON, MA
Held by traders on TradeandTell
No one on the platform currently holds HBIO.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 101,427 | $493.9K |
Insider activity (SEC Form 4)
Stock splits
| Execution date | Ratio |
|---|---|
| 2026-03-16 | 1-for-10reverse |
Recent trades on TradeandTell
No one on the platform has traded HBIO yet.
